Trial Profile
A phase I study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Bevacizumab
- Indications Liver cancer
- Focus Adverse reactions; Biomarker
- 14 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2007 New trial record.